Artiva Biotherapeutics, Inc. (ARTV) Total Return Calculator with Dividends Reinvested

Artiva Biotherapeutics, Inc.

Popular:

The total return for Artiva Biotherapeutics, Inc. (ARTV) stock is +484.52% over the past 12 months. So far it's up 132.15% this year. The 5-year total return is -18.17%, meaning $10,000 invested in ARTV stock 5 years ago would be worth $8,183 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in ARTV 1 year ago, it would be worth $57,778 today — you'd have gained $47,778.

With Dividends Reinvested$57,778+477.78%

Price Only (No DRIP)$57,778+477.78%

Period2025-06-23 → 2026-06-22

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in ARTV

1Y$58,452+$48,452 (+484.5%)484.5% CAGR

3Y$8,183-$1,817 (-18.2%)-6.5% CAGR

5Y$8,183-$1,817 (-18.2%)-3.9% CAGR

10Y$8,183-$1,817 (-18.2%)-2.0% CAGR

15Y$8,183-$1,817 (-18.2%)-1.3% CAGR

20Y$8,183-$1,817 (-18.2%)-1.0% CAGR

30Y$8,183-$1,817 (-18.2%)-0.7% CAGR

Artiva Biotherapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading ARTV total return...

As of 2026-06-23

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+132.15%	—	+132.15%	—	$23,215
1Y	+484.52%	484.52%	+484.52%	—	$58,452
3Y	-18.17%	-6.46%	-18.17%	—	$8,183
5Y	-18.17%	-3.93%	-18.17%	—	$8,183
10Y	-18.17%	-1.98%	-18.17%	—	$8,183
15Y	-18.17%	-1.33%	-18.17%	—	$8,183
20Y	-18.17%	-1.00%	-18.17%	—	$8,183
30Y	-18.17%	-0.67%	-18.17%	—	$8,183

Risk & Highlights

Best Year-16.00%2024

Worst Year-56.97%2025

Max Drawdown-49.22%2026-04-20 → 2026-06-08

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+37.59%	+37.59%	—	+0.41%	+37.2pp
2025	-56.97%	-56.97%	—	+16.64%	-73.6pp
2024	-16.00%	-16.00%	—	+24.00%	-40.0pp

ARTV outperformed the S&P 500 by 459.53pp over the past year (+484.52% vs +24.99%).

Loading summary...

ARTV Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
ARTVArtiva Biotherapeutics, Inc.	$231M	+6.5%	+132.2%	+484.5%	—	-18.2%	-18.2%	-18.2%
FATEFate Therapeutics, Inc.	$251M	+20.8%	+111.1%	+72.7%	—	-64.4%	-97.4%	+4.5%
NKTRNektar Therapeutics	$1.3B	-10.9%	+40.4%	+608.2%	—	+639.2%	-76.1%	-73.3%
STTKShattuck Labs, Inc.	$251M	-17.1%	+33.4%	+408.0%	—	+35.2%	-83.1%	-74.4%
IOVAIovance Biotherapeutics, Inc.	$1.5B	+15.3%	+55.2%	+91.7%	—	-52.8%	-84.2%	-51.2%
CRSPCRISPR Therapeutics AG	$5.2B	+11.4%	+0.6%	+21.7%	—	-4.9%	-57.7%	+283.9%
NTLAIntellia Therapeutics, Inc.	$1.8B	+23.5%	+70.1%	+63.2%	—	-64.1%	-79.4%	-43.2%
BEAMBeam Therapeutics Inc.	$3.7B	+27.3%	+25.8%	+100.9%	—	+2.4%	-59.8%	+82.1%
EDITEditas Medicine, Inc.	$274M	+6.3%	+31.2%	+14.5%	—	-67.8%	-92.5%	-90.9%
KYMRKymera Therapeutics, Inc.	$8.1B	+13.5%	+24.3%	+94.7%	—	+259.0%	+91.0%	+171.9%
ILMNIllumina, Inc.	$24.5B	+14.4%	+20.5%	+79.4%	—	-17.6%	-63.5%	+18.9%

Compare:ARTV vs FATE ARTV vs NKTR ARTV vs STTK ARTV vs FATE vs NKTR

About ARTV Dividend Returns

Artiva Biotherapeutics, Inc. (ARTV) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of ARTV over the past year?

Artiva Biotherapeutics, Inc. (ARTV) delivered a return of 484.52% over the past year. Since ARTV does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in ARTV be worth today?

A $10,000 investment in Artiva Biotherapeutics, Inc. one year ago would be worth $58,452 today, representing a gain of $48,452.

Q3Does ARTV pay dividends?

Artiva Biotherapeutics, Inc. (ARTV) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ARTV, the total return equals the price-only return.

Q4Did ARTV beat the S&P 500?

Yes, Artiva Biotherapeutics, Inc. (ARTV) outperformed the S&P 500 by 459.53 percentage points over the past year. ARTV delivered a total return of 484.52%, compared to the S&P 500's 24.99%. This 459.53pp alpha means investors in ARTV earned more than a passive S&P 500 index fund.

Q5What is ARTV's worst drawdown?

Artiva Biotherapeutics, Inc. (ARTV) experienced a maximum drawdown of -49.22% over the past year, declining from its peak on 2026-04-20 to its trough on 2026-06-08. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is ARTV's long-term total return over 10, 20, or 30 years?

Here are Artiva Biotherapeutics, Inc. (ARTV)'s long-term returns with dividends reinvested. Over 10 years, the total return is -18.2% (-2.0% CAGR) — $10,000 would have grown to $8,183. Over 20 years: -18.2% total return (-1.0% CAGR) — $10,000 → $8,183. Over 30 years: -18.2% total return (-0.7% CAGR) — $10,000 → $8,183. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was ARTV's best and worst year?

Artiva Biotherapeutics, Inc.'s best calendar year was 2024 with a total return of -16.0%. Its worst year was 2025 with a total return of -57.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 41.0 percentage points.

How much would $100/month in ARTV be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →